Reply to: “Comment on ‘Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts’” - 11/02/20
Doi : 10.1016/j.jaad.2019.10.063
Ahmad Nofal, MD a, ⁎ 
, Ayman Marei, MD, PhD b, Al-shimaa M. Ibrahim, MD a, Eman Nofal, MD a, Manal Nabil, MSc a
, Ayman Marei, MD, PhD b, Al-shimaa M. Ibrahim, MD a, Eman Nofal, MD a, Manal Nabil, MSc a a Dermatology Department, Faculty of Medicine, Zagazig University
b Microbiology and Immunology Department, Faculty of Medicine, Zagazig University
∗Correspondence to: Ahmad Nofal, MD, Dermatology Department, Faculty of Medicine, Zagazig University, Zagazig, EgyptDermatology DepartmentFaculty of MedicineZagazig UniversityZagazigEgypt
Il testo completo di questo articolo è disponibile in PDF.
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2019
American Academy of Dermatology, Inc.. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 82 - N° 3
P. e103 - marzo 2020 Ritorno al numero
Articolo precedente
- Comment on: “Intralesional versus intramuscular bivalent human papillomavirus vaccine in the treatment of recalcitrant common warts”
- Arash Taheri, Parisa Mansoori
- Comment on: “Skin changes and manifestations associated with the treatment of obesity”
- Ossama Abbas, Mazen Kurban
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?